Skip to main content
    I

    Ironwood Pharmaceuticals Inc (IRWD)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ

    $4.85
    +0.02 (+0.41%)

    Market Cap: $799.61M

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Ironwood Pharmaceuticals Inc (IRWD) Financials: Revenue, Profit and Cash Flow

    Updated Nov 5, 2026. Financial statements from company filings, amounts in US dollars.

    Ironwood Pharmaceuticals reported revenue of $296.15M for the fiscal year ended Dec 31, 2025, down 15.7% from the year before. That year, net income was $24.02M with a net margin of 8.1%, operating cash flow was $127.04M and free cash flow was $127.01M. The quarter ended Sep 30, 2026 had revenue of $133.04M and net income of $59.84M.

    Revenue and Margins

    The operating margin was 33.3% in the fiscal year ended Dec 2025. Over the 9 years to Dec 2025, revenue grew from $273.96M, a compound annual rate of 0.9%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$296.15M-15.7%100.0%33.3%8.1%
    Dec 2024$351.41M-20.6%100.0%26.5%0.3%
    Dec 2023$442.74M+7.8%100.0%-213.5%-233.0%
    Dec 2022$410.60M-0.8%100.0%61.0%42.6%
    Dec 2021$413.75M+6.2%100.0%56.1%127.7%
    Dec 2020$389.52M-9.1%99.2%36.7%27.3%
    Dec 2019$428.41M+23.6%94.4%28.0%5.0%
    Dec 2018$346.64M+16.2%90.6%-43.5%-81.5%
    Dec 2017$298.28M+8.9%93.6%-5.2%-39.2%
    Dec 2016$273.96MN/A99.3%-18.9%-29.8%
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, net income rose 2629.5% from the year before. In the quarter ended Sep 2026, net income rose 49.3% from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue$296.15M$351.41M$442.74M$410.60M$413.75M$389.52M$428.41M$346.64M$298.28M$273.96M
    Cost of revenue$0$0$0$0$0$3.14M$23.88M$32.75M$19.10M$1.87M
    Gross profit$296.15M$351.41M$442.74M$410.60M$413.75M$386.39M$404.54M$313.89M$279.18M$272.09M
    Research and development$95.14M$111.42M$1.21B$44.27M$70.41M$88.06M$115.04M$101.06M$88.14M$139.49M
    Operating income$98.50M$93.12M-$945.43M$250.34M$232.26M$142.94M$120.12M-$150.67M-$15.36M-$51.87M
    Net income$24.02M$880.00K-$1.03B$175.06M$528.45M$106.18M$21.50M-$282.37M-$116.94M-$81.71M
    EBITDA$100.58M$95.78M-$941.78M$253.79M$256.54M$162.66M$148.83M-$130.01M$10.01M-$16.96M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$133.04M$113.04M$106.51M$47.71M$122.06M$85.24M$41.14M$90.55M$91.59M$94.40M$74.88M$117.55M
    Gross profit$133.04M$113.04M$106.51M$47.71M$122.06M$85.24M$41.14M$90.55M$91.59M$94.40M$74.88M$117.55M
    Operating income$93.13M$79.31M$72.57M$6.80M$75.48M$45.32M-$29.11M$31.49M$25.64M$24.98M$11.02M$37.59M
    Net income$59.84M$51.29M$40.77M-$2.28M$40.08M$23.60M-$37.39M$2.26M$3.65M-$860.00K-$4.16M-$1.75M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, total debt of $584.68M exceeded cash and equivalents by $369.22M. Shareholder equity was negative, at -$261.83M, as total liabilities of $658.74M exceeded total assets of $396.90M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$396.90M$350.91M$471.07M$1.10B$1.13B$559.24M$402.75M$332.05M$605.67M$709.82M
    Current assets$274.18M$182.37M$233.29M$780.63M$745.23M$495.84M$306.85M$266.44M$311.60M$380.18M
    Cash and equivalents$215.46M$88.56M$92.15M$656.20M$620.13M$362.56M$177.02M$173.17M$125.74M$54.00M
    Total liabilities$658.74M$652.24M$817.37M$448.14M$521.02M$496.60M$496.00M$528.42M$595.83M$643.11M
    Short-term debt$199.68M$0$199.56M$0$116.86M$0$1.15M$47.68M$4.32M$20.47M
    Long-term debt$385.00M$583.99M$498.31M$396.25M$337.33M$430.26M$407.99M$366.14M$396.09M$366.49M
    Shareholder equity-$261.83M-$301.33M-$346.30M$652.38M$605.91M$62.64M-$93.25M-$196.37M$9.85M$66.86M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$290.59M$285.13M$434.57M$396.90M$396.06M$342.95M$327.21M$350.91M$389.52M$395.62M$438.82M$471.07M
    Total liabilities$387.79M$446.97M$651.71M$658.74M$660.22M$651.11M$661.27M$652.24M$700.85M$717.35M$769.34M$817.37M
    Cash and equivalents$86.38M$79.13M$220.47M$215.46M$140.41M$92.85M$108.48M$88.56M$88.21M$105.52M$121.54M$92.15M
    Shareholder equity-$97.19M-$161.84M-$217.14M-$261.83M-$264.16M-$308.16M-$334.05M-$301.33M-$311.33M-$321.73M-$330.52M-$346.30M
    Last 12 quarters

    Cash Flow

    In the fiscal year ended Dec 2025, free cash flow was 100.0% of operating cash flow.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow$127.04M$103.55M$183.43M$273.76M$261.89M$168.84M$10.72M-$70.88M-$100.75M-$25.93M
    Capital expenditures$34.00K$142.00K$273.00K$136.00K$265.00K$1.84M$7.19M$351.00K$2.80M$4.21M
    Free cash flow$127.01M$103.41M$183.15M$273.63M$261.63M$166.99M$3.54M-$71.23M-$103.56M-$30.14M
    Dividends paidN/AN/A$26.31M$0$0N/AN/AN/A$0$0
    Share repurchasesN/AN/A$0$126.39M$24.13M$0N/AN/AN/AN/A
    Investing cash flow-$34.00K-$142.00K-$1.03B-$136.00K-$265.00K-$1.84M-$11.14M$88.87M$151.46M-$177.67M
    Financing cash flow$216.00K-$106.97M$277.16M-$237.55M-$4.55M$18.55M-$1.19M$30.07M$19.84M-$4.18M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow$67.40M$58.28M$5.12M$74.58M$47.58M-$15.07M$19.95M$15.21M$9.88M$33.47M$44.98M$35.83M
    Capital expendituresN/AN/A$0$1.00K$2.00K$2.00K$31.00K$16.00K$16.00K$58.00K$68.00K$211.00K
    Free cash flowN/AN/A$5.12M$74.57M$47.58M-$15.07M$19.92M$15.20M$9.87M$33.41M$44.92M$35.62M
    Last 12 quarters

    Frequently Asked Questions About IRWD

    What is Ironwood Pharmaceuticals' annual revenue?

    Ironwood Pharmaceuticals reported revenue of $296.15M for the fiscal year ended Dec 31, 2025.

    How fast is Ironwood Pharmaceuticals' revenue growing?

    Revenue was down 15.7% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was -10.3%.

    Is Ironwood Pharmaceuticals profitable?

    Yes. Ironwood Pharmaceuticals reported net income of $24.02M for the fiscal year ended Dec 31, 2025, with a net margin of 8.1%.

    How much free cash flow does IRWD generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of $127.04M minus capital expenditures of $34.00K produced free cash flow of $127.01M.

    How much debt does Ironwood Pharmaceuticals have?

    The balance sheet dated Dec 31, 2025 reported long-term debt of $385.00M, short-term debt of $199.68M and cash and equivalents of $215.46M.